Athena Athena

X
[{"orgOrder":0,"company":"Evonik","sponsor":"Cassava Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik and Cassava Sciences Join Forces to Fight Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Evonik","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Evonik","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Evonik","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evonik Invests US$220 Million in Partnership with The U.S. Government to Build New Lipid Production Facility For mRNA-Based Therapies in The U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Evonik","sponsor":"Allay Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pain Therapy Implants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Evonik Industries

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.

            Lead Product(s): Bupivacaine

            Therapeutic Area: Neurology Product Name: ATX-101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Allay Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 13, 2022

            Details:

            Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.

            Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Triple Pack

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Phathom Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 24, 2022

            Details:

            Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell, where it is released.

            Lead Product(s): mRNA-based Therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $220.0 million Upfront Cash: Undisclosed

            Deal Type: Funding June 02, 2022

            Details:

            Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.

            Lead Product(s): Simufilam

            Therapeutic Area: Neurology Product Name: PTI-125

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cassava Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 09, 2021

            Details:

            Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership between Evonik and the Comirnaty, vaccine manufacturer BioNTech.

            Lead Product(s): Tozinameran

            Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: BioNTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 11, 2021

            Post Enquiry
            POST ENQUIRY